氨甲环酸
纤溶酶
纤溶
医学
2019年冠状病毒病(COVID-19)
凝血病
冠状病毒
免疫学
病毒学
药理学
疾病
内科学
传染病(医学专业)
生物
外科
生物化学
失血
酶
作者
Hayder M Al-Kuraishy,Ali I. Al‐Gareeb,Nasser A. Hadi Al-Harcan,Αθανάσιος Αλεξίου,Gaber El‐Saber Batiha
出处
期刊:Endocrine, metabolic & immune disorders
[Bentham Science]
日期:2023-01-06
卷期号:23 (1): 35-45
被引量:9
标识
DOI:10.2174/1871530322666220801102402
摘要
Coronavirus disease 2019 (COVID-19) is caused by a severe acute respiratory syndrome, coronavirus type 2 (SARS-CoV-2), leading to acute tissue injury and an overstated immune response. In COVID-19, there are noteworthy changes in the fibrinolytic system with the development of coagulopathy. Therefore, modulation of the fibrinolytic system may affect the course of COVID-19. Tranexamic acid (TXA) is an anti-fibrinolytic drug that reduces the conversion of plasminogen to plasmin, which is necessary for SARS-CoV-2 infectivity. In addition, TXA has anti-inflammatory, anti-platelet, and anti-thrombotic effects, which may attenuate the COVID-19 severity. Thus, in this narrative review, we try to find the beneficial and harmful effects of TXA in COVID-19.
科研通智能强力驱动
Strongly Powered by AbleSci AI